Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study
Daniel A. Pollyea
, Keith Pratz
, Anthony Letai
, Brian A. Jonas
, Andrew H. Wei
, Vinod Pullarkat
,
Marina Konopleva
, Michael J. Thirman
, Martha Arellano
, Pamela S. Becker
, Brenda Chyla
, Wan Jen Hong
, Qi Jiang
, Jalaja Potluri
, Courtney D. DiNardo
Research output
:
Contribution to journal
›
Article
›
peer-review
134
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Newly Diagnosed
100%
Acute Myeloid Leukemia
100%
Decitabine
100%
Azacitidine
100%
Venetoclax
100%
Phase 1b Study
100%
Complete Remission
50%
Intensive Chemotherapy
25%
Follow-up Time
12%
Median Overall Survival
12%
Neutropenia
12%
Thrombocytopenia
12%
Response Rate
12%
Duration of Response
12%
Anemia
12%
Overall Survival
12%
Blood Count
12%
Highly Effective
12%
Febrile Neutropenia
12%
Hypomethylating Agents
12%
Leukemia Therapy
12%
Safety Response
12%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Decitabine
100%
Azacitidine
100%
Venetoclax
100%
Remission
50%
Overall Survival
25%
Chemotherapy
25%
Neutropenia
12%
Thrombocytopenia
12%
Anemia
12%
Febrile Neutropenia
12%